Cadence Pharmaceuticals to Host Analyst and Investor Day
SAN DIEGO, Nov. 28, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that the company will host an Analyst and Investor Day for financial analysts on Thursday, December 6, 2012, from 9:00 am to 12:00 pm EST in New York, NY. Members of the Cadence senior management team will provide an update on the OFIRMEV® (acetaminophen) injection launch, as well as the Company's operations and business development plans. In addition, there will be two presentations by outside experts discussing their experience with OFIRMEV.
- David J. Cziperle, M.D., FACS, Clinical Assistant Professor Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Director Thoracic and Cardiovascular Surgery Silver Cross Hospital
- John Marshall, PharmD, BCPS, Clinical Coordinator – Critical Care, Beth Israel Deaconess Medical Center
Presentations will begin at 9:00 am EST. For additional information and registration, please e-mail [email protected], or call 858-356-5930.
A live webcast of the event will be accessible from the Company's website at investors.cadencepharm.com. Please allow extra time prior to the webcast to visit the site and download any streaming media software that may be required to listen to the broadcast. The event will be archived on the Company web site for 90 days.
About OFIRMEV® (Acetaminophen) Injection
OFIRMEV (acetaminophen) injection (1000 mg / 100 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.
Important Safety Information
Do not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.
For more information, please see the complete OFIRMEV Prescribing Information, available at www.OFIRMEV.com or www.cadencepharm.com.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the "Investors" page of www.cadencepharm.com under "Events and Presentations."
Cadence® and OFIRMEV® are trademarks of Cadence Pharmaceuticals, Inc.
Contact: |
William R. LaRue |
SVP, CFO |
|
Cadence Pharmaceuticals, Inc. |
|
858-436-1400 |
SOURCE Cadence Pharmaceuticals, Inc.
Share this article